QasimW, H ZhanS S, amarasingheS A, damsP A, mroliaS S, taffordK B, utlerC R, ivatG Wright, et al. (2017). Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med, 9:eaaj2013.
2.
KimS, D KimSW, ChoJ K, im and JS Kim. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res, 24:1012–1019.
3.
HendelA, RO BakJT, ClarkAB, KennedyDE, RyanS R, oyI S, teinfeldBD, LunstadRJKaiser, et al. (2015). Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol, 33:985–989.
4.
DeverDP, RO BakA R, einischJ C, amarenaG W, ashingtonCE, NicolasM P, avel-DinuN S, axenaABWilkens, et al. (2016). CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature, 539:384–389.
5.
EyquemJ, J Mansilla-SotoT G, iavridisSJ, van der StegenM H, amiehKM, CunananA O, dakM G, onen and SadelainM. (2017). Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature, 543:113–117.
6.
YangY, E Jacoby and TJ Fry. (2015). Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol, 22:509–515.
